Four consecutive earnings beats averaging approximately 11% above consensus and free cash flow converting at roughly 3x reported net income demonstrate operational and cash generation strength; however, the stock has moved above its near-term resistance target with an unfavorable risk/reward setup and overbought momentum readings at an RSI of 83, arguing for patience rather than action at current prices.
Thesis pillars
- Sole Supplier Concentration Risk↓Deteriorating
- Consistent Earnings Beat Streak→Stable
- Exceptional Free Cash Generation→Stable
- +1 more pillar — see the Why tab for full reasoning
Cardinal Health, Inc. (CAH) Stock Analysis
Healthcare · Medical Distribution
Sell if holding. Engine safety override at $224.67: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.82; Below-average business quality; Negative price momentum.
Cardinal Health distributes pharmaceuticals and makes/distributes medical, surgical, and laboratory products, plus runs nuclear pharmacy, at-Home medical supply, and logistics businesses. Its largest customer, CVS Health, was 30% of fiscal 2025 revenue (43% for its top five... Read more
Sell if holding. Engine safety override at $224.67: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.82; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.7/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 43d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
About Cardinal Health, Inc.
About Cardinal Health, Inc.
Cardinal Health's largest customer, CVS Health, accounted for 30% of fiscal 2025 revenue, and its top five customers together made up 43%, while its two largest GPOs, Vizient and Premier, drove a further 27% of revenue. The company runs a Pharmaceutical distribution business alongside its Global Medical Products and Distribution (GMPD) segment, making Cardinal Health-branded surgical and lab products, and expanded into physician services in fiscal 2025 via acquisitions of ADS ($1.1B), GI Alliance ($2.8B), and ION ($1.1B).
Cardinal Health earns most of its revenue by distributing pharmaceuticals and medical, surgical, and laboratory products to pharmacies, hospitals, ambulatory surgery centers, and clinical laboratories in the U.S. and Canada, supplementing distributed national-brand products with its own generally higher-margin Cardinal Health-branded GMPD product lines such as exam and surgical gloves, wound care, and urology supplies. Its Red Oak Sourcing joint venture with CVS Health, running through June 2029, negotiates generic pharmaceutical supply contracts on behalf of both companies, tying Cardinal Health's largest customer relationship into its sourcing economics as well as its distribution volume. Beyond core distribution, the company has built out specialty physician-services platforms through a string of fiscal 2025 acquisitions — GI Alliance and its Urology America add-on, Integrated Oncology Network, and Specialty Networks — while its Nuclear and Precision Health Solutions segment manufactures and delivers radiopharmaceuticals, including contract manufacturing of Xofigo and North American rights to Lymphoseek.
Show full overview
Cardinal Health's concentration risk is doubled up with a single counterparty: CVS Health is both its largest customer at 30% of fiscal 2025 revenue and, through the Red Oak Sourcing joint venture running through June 2029, a co-negotiator of the generic pharmaceutical supply contracts that determine Cardinal Health's own input costs. That dual relationship means a deterioration in the CVS partnership would pressure Cardinal Health simultaneously on the revenue side and the sourcing side, a structural linkage the filing does not disclose for any of its other four largest customers or its five largest suppliers, whose combined 37% of revenue is comparatively diffuse.
See also: Healthcare · Medical Distribution
From Cardinal Health, Inc.'s most recent 10-K filing, extracted August 30, 2026.
Recent developments
updated 2026-09-23Recent Developments — Cardinal Health, Inc.
Latest news
- NEWS 9 Health Care Stocks Whale Activity In Today’s Session — benzinga Sep 18, 2026 neutral
- NEWS RBC Capital Initiates Coverage On Cardinal Health with Outperform Rating, Announces Price Target of $276 — benzinga Aug 19, 2026 positive
- NEWS TD Cowen Maintains Buy on Cardinal Health, Raises Price Target to $280 — benzinga Aug 13, 2026 positive
- NEWS JP Morgan Maintains Neutral on Cardinal Health, Raises Price Target to $260 — benzinga Aug 13, 2026 positive
- NEWS Barclays Maintains Overweight on Cardinal Health, Raises Price Target to $275 — benzinga Aug 13, 2026 positive
Generated 2026-09-23T17:57:06Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomerCVS Health30%10-K Item 1: 'Our largest customer, CVS Health, accounted for 30 percent of our fiscal 2025 revenue.'
- MEDIUMCustomerfive largest customers43%10-K Item 1: 'In the aggregate, our five largest customers, including CVS Health, accounted for 43 percent of our fiscal 2025 revenue.'
- MEDIUMcounterpartyVizient and Premier GPOs27%10-K Item 1: 'Sales to members of these two GPOs, under numerous contracts across our businesses, collectively accounted for 27 percent of our revenue in fiscal 2025.'
- MEDIUMSupplierfive largest suppliers37%10-K Item 1: 'During fiscal 2025, revenue resulting from sales of products obtained from our five largest suppliers accounted for an aggregate of 37 percent of our revenue and our largest supplier’s products accounted for approximately 9 percent of revenue.'
- LOWSupplierlargest supplier9.0%10-K Item 1: 'During fiscal 2025, revenue resulting from sales of products obtained from our five largest suppliers accounted for an aggregate of 37 percent of our revenue and our largest supplier’s products accounted for approximately 9 percent of revenue.'
Material Events(8-K, last 90d)
- 2026-03-23Item 5.02LOWBoard Chair Gregory B. Kenny notified Cardinal Health on March 17, 2026 of his decision to retire from the Board and as Board Chair, effective March 20, 2026, citing no disagreement with the company. Director Patricia A. Hemingway Hall was immediately appointed as successor Board Chair.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $224.67: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.82; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $214.61. Score 5.7/10, moderate confidence.
Take-profit target: $243.84 (+8.5% upside). Prior stop was $214.61. Stop-loss: $214.61.
Quality below floor (3.6 < 4.0).
Cardinal Health, Inc. trades at a P/E of 31.2 (forward 15.8). TrendMatrix value score: 6.5/10. Verdict: Sell.
24 analysts cover CAH with a consensus score of 4.2/5. Average price target: $271.
What does Cardinal Health, Inc. do?Cardinal Health distributes pharmaceuticals and makes/distributes medical, surgical, and laboratory products, plus runs...
Cardinal Health distributes pharmaceuticals and makes/distributes medical, surgical, and laboratory products, plus runs nuclear pharmacy, at-Home medical supply, and logistics businesses. Its largest customer, CVS Health, was 30% of fiscal 2025 revenue (43% for its top five customers), while two GPOs (Vizient, Premier) drove 27% of revenue and its top five suppliers accounted for 37%.